S
Steven A. Feldman
Researcher at Stanford University
Publications - 79
Citations - 15742
Steven A. Feldman is an academic researcher from Stanford University. The author has contributed to research in topics: Chimeric antigen receptor & Antigen. The author has an hindex of 35, co-authored 79 publications receiving 12812 citations. Previous affiliations of Steven A. Feldman include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
TL;DR: CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Journal ArticleDOI
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins,Richard A. Morgan,Steven A. Feldman,James Chih-Hsin Yang,Richard M. Sherry,Mark E. Dudley,John R. Wunderlich,Azam V. Nahvi,Lee J. Helman,Crystal L. Mackall,Udai S. Kammula,Michael S. Hughes,Nicholas P. Restifo,Mark Raffeld,Chyi-Chia Richard Lee,Catherine Levy,Yong F. Li,Mona El-Gamil,Susan L. Schwarz,Carolyn M. Laurencot,Steven A. Rosenberg +20 more
TL;DR: These observations indicate that TCR-based gene therapies directed against NY-ESO-1 represent a new and effective therapeutic approach for patients with melanoma and synovial cell sarcoma.
Journal ArticleDOI
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
James N. Kochenderfer,Mark E. Dudley,Steven A. Feldman,Wyndham H. Wilson,David Spaner,Irina Maric,Maryalice Stetler-Stevenson,Giao Q. Phan,Michael S. Hughes,Richard M. Sherry,James Chih-Hsin Yang,Udai S. Kammula,Laura Devillier,Robert J. Carpenter,Debbie Ann N. Nathan,Richard A. Morgan,Carolyn M. Laurencot,Steven A. Rosenberg +17 more
TL;DR: Pro adoptive transfer of T cells genetically modified to express an anti-CD19 chimeric Ag receptor (CAR) has great promise to improve the treatment of B-cell malignancies because of a potent ability to eradicate CD19(+) cells in vivo; however, reversible cytokine-associated toxicities occurred after CAR-transduced T-cell infusions.
Journal ArticleDOI
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer,Wyndham H. Wilson,John E. Janik,Mark E. Dudley,Maryalice Stetler-Stevenson,Steven A. Feldman,Irina Maric,Mark Raffeld,Debbie Ann N. Nathan,Brock J. Lanier,Richard A. Morgan,Steven A. Rosenberg +11 more
TL;DR: A patient with advanced follicular lymphoma was treated by administering a preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B- cell antigen CD19, and B-cell precursors were selectively eliminated from the patient's bone marrow after infusion of anti-CD19-CAR-transduced T cells.
Journal ArticleDOI
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
Richard A. Morgan,Nachimuthu Chinnasamy,Daniel Abate-Daga,Alena Gros,Paul F. Robbins,Zhili L. Zheng,Mark E. Dudley,Steven A. Feldman,James Chih-Hsin Yang,Richard M. Sherry,Giao Q. Phan,Michael S. Hughes,Udai S. Kammula,Akemi D. Miller,Crystal J. Hessman,Ashley A. Stewart,Nicholas P. Restifo,Martha Quezado,Meghna Alimchandani,Avi Z. Rosenberg,Avindra Nath,Tongguang G. Wang,Bibiana Bielekova,Simone C. Wuest,Nirmala Akula,Francis J. McMahon,Susanne Wilde,Barbara Mosetter,Dolores J. Schendel,Carolyn M. Laurencot,Steven A. Rosenberg +30 more
TL;DR: Molecular assays of human brain samples indicated that MAGE-A12 was expressed in human brain, possibly the initiating event of a TCR-mediated inflammatory response that resulted in neuronal cell destruction and raises caution for clinical applications targeting Mage-A family members with highly active immunotherapies.